Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Genetic engineering deployed to insert gene for human insulin into a bacterium, thus harnessing the substance for widespread ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

Indianapolis-based drugmaker Eli Lilly and Company has announced price reductions of 70% for its most commonly prescribed insulins, as well as expansion of its Insulin Value Program, capping ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

The rising price of insulin has become one of the most talked about issues across the pharma industry. Ben Hargreaves explains how Eli Lilly decided to cap its insulin price, why it has decided to ...